Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
about
BH3 mimetics to improve cancer therapy; mechanisms and examplesPotential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Bcl-2 antagonists: a proof of concept for CLL therapyAldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical applicationTargeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancerThe immunosuppressive effect of gossypol in mice is mediated by inhibition of lymphocyte proliferation and by induction of cell apoptosis.Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor.Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells.RhoA/ROCK/PTEN signaling is involved in AT-101-mediated apoptosis in human leukemia cells in vitro and in vivo.An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.(-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivoChemotherapeutic approaches for targeting cell death pathways.A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer.Gossypol Acetic Acid Prevents Oxidative Stress-Induced Retinal Pigment Epithelial Necrosis by Regulating the FoxO3/Sestrin2 Pathway.Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer.The mitochondrial death pathway: a promising therapeutic target in diseasesSmall-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1Evaluation of anticancer properties of a decoction containing Adenanthera pavonina L. and Thespesia populnea LSynthesis of Hemigossypol and its DerivativesIonizing radiation induces myofibroblast differentiation via lactate dehydrogenaseIn vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castrationInvestigations on gossypol: past and present developments.Pharmacologic inhibition of lactate production prevents myofibroblast differentiation.The apoptosome: emerging insights and new potential targets for drug designDouble-layered hyaluronic acid/stearic acid-modified polyethyleneimine nanoparticles encapsulating (-)-gossypol: a nanocarrier for chiral anticancer drugs.Mitochondrial permeability transition pore as a selective target for anti-cancer therapyGossypol-Induced Differentiation in Human Leukemia HL-60 Cells.Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects.Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cellsExpanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis.Aldehyde dehydrogenase is used by cancer cells for energy metabolism.Aldehyde dehydrogenase inhibition combined with phenformin treatment reversed NSCLC through ATP depletion.Small mitochondria-targeting molecules as anti-cancer agents.Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.Apoptosis-modulating drugs for improved cancer therapy.A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia.Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors.
P2860
Q24655483-A307C892-BEE4-4FE8-A702-52A419F4A7DAQ26771601-BAEECE7F-F3AA-43EF-B800-69FA9A3EADF5Q26823996-2E000CD2-21A0-4D90-BFB9-D55E6EF0A783Q28265682-383F1223-3D73-46E1-8873-DCF936DFE53FQ30983828-6B9946C6-28B7-445A-9ABC-07D23882371CQ33429568-EC237D92-4358-482E-B2BD-666B482FF8EBQ33632423-E517BF1F-7DDC-4F60-BE10-CC0389F619F9Q33647720-C187553D-0832-43E2-8265-885D0B55BB19Q33695176-13960221-DB18-4E60-9EC4-AD1106047A72Q34066960-B5C839FA-8522-41BB-87D4-9850D71216CCQ35052194-839160C4-9F0D-4B1F-8A34-93A09D94E273Q35094229-005E9CB4-FAD1-417D-9E73-7C86E7008AE1Q35234305-D733F9F5-9A28-468D-9E75-5D65BA303E45Q35573017-2EE0E651-3F1F-4358-8A59-B02B128828E7Q35643843-C422C109-7E2B-4786-B95D-D4C711364F42Q35743521-05AE5945-7905-4F0E-9F9E-8D2CE3B086D0Q35831981-345B80AA-3ABC-4035-81B5-810EC7BC96BDQ35876252-F6C56D2F-7A99-4D67-B296-23B801D896AFQ35929218-4BE8BCED-3884-4874-B5E3-BE654E5C0684Q36112046-E8FEFB39-5339-465F-8711-FF3F1CEA525BQ36174551-F47E3D96-0744-496D-9156-A428C75BEC63Q36259619-15AB2266-D74F-4D29-BE9C-6C3DF22B7B8FQ36300043-0A670951-066A-4FD8-9EAF-7A051417BB58Q36345864-A40F6335-745E-4DA5-B5AD-097F88DD4838Q36517696-9DDAD34D-95B4-4218-B871-FD4C244C9338Q36584941-FA31D8DC-3BB9-4166-9F26-438B6E5CA5E9Q36668047-33640A55-7DF1-40E9-9822-C71F2856E47FQ36735281-2BB9F7A2-A084-42FD-A5C7-07065ADD64AFQ36804432-BFBF102D-7DE6-4A51-A687-7929794577B9Q36843766-79809BC1-6FC3-428F-80C6-4539C9A27DDEQ37124747-DAAEC3D8-5CCC-4465-9714-C1E8E33C09CDQ37284056-61242EDB-DAE4-4886-8966-87002CA87618Q37406947-F348C296-7061-4263-8064-C9B4748FA5DAQ37463894-F9E4BCB4-3C69-4278-843D-3E12ECB29763Q37580239-2426C519-AB82-4F46-B4C1-3BDA15069F7DQ37648872-B191E2E6-5B75-46AF-9750-BC3676C71042Q37778876-42AC08A2-DA8B-4CFF-8D3B-DF12EC033A81Q38005914-995026CD-FEAC-43A1-910C-4EB65FE155A7Q38061861-55A292E9-C559-4148-8DB8-9EFFFE6E123BQ38076345-30764EF8-01E3-4C69-A281-AA3E69908A1E
P2860
Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@en
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@nl
type
label
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@en
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@nl
prefLabel
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@en
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@nl
P2093
P2860
P356
P1476
Oral gossypol in the treatment ...... : a phase I/II clinical trial.
@en
P2093
Ligueros M
Moasser MM
Reidenberg MM
Seidman AD
P2860
P2888
P304
P356
10.1023/A:1010686204736
P407
P50
P577
2001-04-01T00:00:00Z
P6179
1025979799